Instituto Bernabeu highlights the value of anti-Müllerian hormone for personalizing stimulation at the 3rd Symposium on Controversies in Reproductive and Perinatal Medicine

Instituto Bernabeu took part in the 3rd Symposium on Controversies in Reproductive and Perinatal Medicine, held in Madrid at the end of January. The team from Instituto Bernabeu Madrid contributed with a presentation titled: “Anti-Müllerian Hormone (AMH) and Reproductive Counseling.”

The clinic explains that this hormone, produced by the ovaries, has been used for nearly 20 years as a practical equivalent of the number of eggs a woman has available.

Initially, anti-Müllerian hormone was limited to the field of reproductive medicine. Today, thanks mainly to technological developments, it can be accessed by patients from their homes and outside the medical setting, according to Instituto Bernabeu Madrid.

“In clinical practice, it is a very useful parameter to personalize ovarian stimulation for our patients and to set realistic expectations for treatment, as the state of ovarian reserve often correlates with the response to stimulation,” the team explains. This is especially important for patients with low ovarian reserve, as having this information helps alert the specialist and allows for the use of additional techniques to improve the patient’s prognosis.